R Michael Tuttle

List of Publications by Citations

Source: https://exaly.com/author-pdf/2346573/r-michael-tuttle-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60 26,401 162 205 h-index g-index citations papers 6.88 6.3 31,539 234 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
205	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i> , 2016 , 26, 1-133	6.2	6910
204	Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. <i>Thyroid</i> , 2009 , 19, 1167-214	6.2	5121
203	Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. <i>Thyroid</i> , 2006 , 16, 109-42	6.2	1553
202	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. <i>JAMA Oncology</i> , 2016 , 2, 1023-9	13.4	895
201	Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. <i>Thyroid</i> , 2010 , 20, 1341-9	6.2 9	606
200	Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA - Journal of the American Medical Association, 2013 , 309, 1493-501	27.4	605
199	American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. <i>Thyroid</i> , 2012 , 22, 1104-39	6.2	524
198	The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. <i>Thyroid</i> , 2012 , 22, 1144-52	6.2	499
197	Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 498-505	5.6	431
196	Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. <i>Cancer Research</i> , 2009 , 69, 488	15 ¹ 93 ¹	403
195	Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 42-50	2.2	345
194	Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. <i>Cancer</i> , 2006 , 107, 1255-64	6.4	307
193	Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. <i>Cancer</i> , 2011 , 117, 4439-46	6.4	220
192	Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. JAMA Otolaryngology - Head and Neck Surgery, 2017 , 143, 1015-1020	3.9	219
191	Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. <i>Cancer</i> , 2006 , 106, 1286-95	6.4	201
190	A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. <i>Thyroid</i> , 2016 , 26, 144-9	6.2	185
189	American Thyroid Association statement on outpatient thyroidectomy. <i>Thyroid</i> , 2013 , 23, 1193-202	6.2	181

(2009-2000)

188	The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 1170-5	5.6	166
187	Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. <i>Clinical Endocrinology</i> , 2012 , 77, 132-8	3.4	165
186	American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. <i>Thyroid</i> , 2012 , 22, 237-44	6.2	156
185	Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. <i>Thyroid</i> , 2001 , 11, 1169-75	6.2	143
184	Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?. <i>Lancet Diabetes and Endocrinology,the</i> , 2016 , 4, 933-942	18.1	140
183	Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2018 , 68, 55-63	220.7	136
182	Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. <i>Clinical Endocrinology</i> , 2011 , 75, 112-9	3.4	135
181	Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 2692-700	5.6	134
180	Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. <i>Journal of Nuclear Medicine</i> , 2008 , 49, 764-70	8.9	125
179	Changing Trends in the Incidence of Thyroid Cancer in the United States. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016 , 142, 709-11	3.9	124
178	An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer. <i>Thyroid</i> , 2016 , 26, 373-80	6.2	122
177	Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 1587-91	8.9	122
176	Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European	6.2	119
175	Thyroid Association. <i>Thyroid</i> , 2019 , 29, 461-470 Thyroid carcinoma, version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1671-80; quiz 1680	7-3	113
174	Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3242	<u>5</u> 4	113
173	Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems. <i>Thyroid</i> , 2013 , 23, 1401-7	6.2	111
172	Update on differentiated thyroid cancer staging. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014 , 43, 401-21	5.5	108
171	Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). <i>Thyroid</i> , 2009 , 19, 119-27	6.2	106

170	Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. <i>Human Pathology</i> , 2015 , 46, 657-64	3.7	103
169	Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. <i>Thyroid</i> , 2012 , 22, 575-84	6.2	95
168	Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. <i>Thyroid</i> , 2015 , 25, 300-7	6.2	94
167	Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. <i>Thyroid</i> , 2011 , 21, 845-53	6.2	94
166	The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1361-7	8.9	92
165	A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. <i>Journal of Nuclear Medicine</i> , 2002 , 43, 1482-8	8.9	90
164	In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. <i>Thyroid</i> , 2011 , 21, 1317-22	6.2	86
163	Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. Journal of Nuclear Medicine, 2009 , 50, 1605-10	8.9	82
162	Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. <i>Thyroid</i> , 2017 , 27, 512-517	6.2	81
161	Follow up approaches in thyroid cancer: a risk adapted paradigm. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008 , 37, 419-35, ix-x	5.5	81
160	Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 1417-1428	5.6	80
159	Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?. <i>Thyroid</i> , 2015 , 25, 1106-1	46.2	79
158	Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. <i>Thyroid</i> , 2015 , 25, 15-27	6.2	79
157	Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. <i>Modern Pathology</i> , 2001 , 14, 289-96	9.8	79
156	Management of advanced medullary thyroid cancer. Lancet Diabetes and Endocrinology,the, 2016, 4, 64-	718.1	75
155	The History of the Follicular Variant of Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 15-22	5.6	73
154	Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer. <i>Annals of Surgical Oncology</i> , 2016 , 23, 410-5	3.1	71
153	The impact of nodal status on outcome in older patients with papillary thyroid cancer. <i>Surgery</i> , 2014 , 156, 137-46	3.6	71

Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of and as Novel Thyroid Cancer Genes Associated with Tumor Virulence. <i>Clinical Cancer Research</i> , 2017 , 23, 5970-	-5 98 0	64	
Risk-adapted management of thyroid cancer. <i>Endocrine Practice</i> , 2008 , 14, 764-74	3.2	63	
Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 6010-6	5.6	63	
Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. <i>Modern Pathology</i> , 2016 , 29, 985-95	9.8	62	
The Chernobyl accident and its consequences: update at the millennium. <i>Seminars in Nuclear Medicine</i> , 2000 , 30, 133-40	5.4	62	
Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. <i>Thyroid</i> , 2012 , 22, 778-83	6.2	61	
European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. <i>Thyroid</i> , 2019 , 29, 7-26	6.2	59	
Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. <i>Thyroid</i> , 2012 , 22, 1007-15	6.2	56	
Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 717-722	8.9	55	
Papillary thyroid cancer: monitoring and therapy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007 , 36, 753-78, vii	5.5	55	
Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. <i>Cancer</i> , 2017 , 123, 2955-2964	6.4	53	
Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. <i>Thyroid</i> , 2010 , 20, 257-63	6.2	53	
Prophylactic central neck dissection in differentiated thyroid cancer: an assessment of the evidence. <i>Annals of Surgical Oncology</i> , 2013 , 20, 2285-9	3.1	52	
Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. <i>Thyroid</i> , 2015 , 25, 242-9	6.2	51	
Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. <i>Thyroid</i> , 2020 , 30, 1505-1517	6.2	51	
Medical management of thyroid cancer: a risk adapted approach. <i>Journal of Surgical Oncology</i> , 2008 , 97, 712-6	2.8	50	
American Thyroid Association statement on the essential elements of interdisciplinary communication of perioperative information for patients undergoing thyroid cancer surgery. <i>Thyroid</i> , 2012 , 22, 395-9	6.2	49	
Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates. <i>Cancer</i> , 2015 , 121, 1793-9	6.4	48	
	Novel Thyroid Cancer Genes Associated with Tumor Virulence. <i>Clinical Cancer Research</i> , 2017, 23, 5970 Risk-adapted management of thyroid cancer. <i>Endocrine Practice</i> , 2008, 14, 764-74 Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 6010-6 Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. <i>Modern Pathology</i> , 2016, 29, 985-95 The Chernobyl accident and its consequences: update at the millennium. <i>Seminars in Nuclear Medicine</i> , 2000, 30, 133-40 Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroid-accident and its consequences: update at the millennium. <i>Seminars in Nuclear Medicine</i> , 2000, 2012, 22, 778-80 European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. <i>Thyroid</i> , 2019, 29, 7-26 Recombinant human thyroid stimulating hormone-assisted radioactive indine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. <i>Thyroid</i> , 2012, 22, 1007-15 Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive lodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 59, 177-722 Papillary thyroid cancer: monitoring and therapy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007, 36, 753-78, vii Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. <i>Cancer</i> , 2017, 123, 2955-2964 Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid sungital Oncology	Risk-adapted management of thyroid cancer. Endocrine Practice, 2008, 14, 764-74 3.2 Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 6010-6 Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETVG-NTRK3 fusion. Modern Pathology, 2016, 29, 985-95 The Chernobyl accident and its consequences: update at the millennium. Seminars in Nuclear Medicine, 2000, 30, 133-40 Even without additional therapy, serum thyroglobulin concentrations often decline for years after botal thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid, 2012, 22, 778-83 European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid, 2019, 29, 7-26 Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid, 2012, 22, 1007-15 Comparison of Empiric Versus Whole-Body/Blood Clearance Dosimetry-Based Approach to Radioactive lodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2017, 58, 717-722 Papillary thyroid cancer: monitoring and therapy. Endocrinology and Metabolism Clinics of North America. 2007, 36, 753-78. vii Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multivinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. Cancer, 2017, 123, 2955-2944 Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid, 2012, 02, 257-63 Prophylactic central neck	Risk-adapted management of thyroid cancer, Endocrine Practice, 2008, 14, 764-74 3.2 6.3 Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 6010-6 Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-HTRK3 fusion. Modern Pathology, 2016, 29, 985-95 The Chernobyl accident and its consequences: update at the millennium. Seminars in Nuclear Medicine, 2000, 30, 133-40 Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroide doctomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid, 2012, 22, 778-83 European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid, 2019, 29, 7-26 Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid, 2012, 22, 1007-15 Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive lodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2017, 88, 717-72. Papillary thyroid cancer: monitoring and therapy. Endocrinology and Metabolism Clinics of North America, 2007, 36, 753-78, vii Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. Cancer, 2017, 123, 2955-2964 Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid, 2017, 123, 2955-2964 Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. Thyroid, 2015, 2, 2

134	Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 ,	5.6	47
133	External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. <i>Head and Neck</i> , 2016 , 38, 493-8	4.2	46
132	Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics. <i>Thyroid</i> , 2017 , 27, 632-640	6.2	44
131	A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients. <i>Thyroid</i> , 2013 , 23, 436-42	6.2	44
130	Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	43
129	Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: a clinicopathologic study of 276 cases. <i>Human Pathology</i> , 2015 , 46, 1789-98	3.7	42
128	Prognostic factors in papillary microcarcinoma with emphasis on histologic subtyping: a clinicopathologic study of 148 cases. <i>Thyroid</i> , 2014 , 24, 245-53	6.2	42
127	Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. <i>Thyroid</i> , 2012 , 22, 877-83	6.2	42
126	Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors. <i>Thyroid</i> , 2007 , 17, 543-7	6.2	42
125	Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1 cm. <i>Journal of Thyroid Research</i> , 2013 , 2013, 398194	2.6	40
124	Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local Failure. <i>Thyroid</i> , 2015 , 25, 993-8	6.2	39
123	Multi-institutional validation of a novel textural analysis tool for preoperative stratification of suspected thyroid tumors on diffusion-weighted MRI. <i>Magnetic Resonance in Medicine</i> , 2016 , 75, 1708-1	6 ^{4·4}	39
122	Pediatric Differentiated Thyroid Carcinoma of Follicular Cell Origin: Prognostic Significance of Histologic Subtypes. <i>Thyroid</i> , 2016 , 26, 219-26	6.2	38
121	Ret/PTC activation in benign and malignant thyroid tumors arising in a population exposed to low-dose external-beam irradiation in childhood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2281-9	5.6	38
120	Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases. <i>Thyroid</i> , 2014 , 24, 1088-95	6.2	37
119	Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?. <i>Endocrine</i> , 2018 , 59, 143-150	4	37
118	Surgical management of the recurrent laryngeal nerve in thyroidectomy: American Head and Neck Society Consensus Statement. <i>Head and Neck</i> , 2018 , 40, 663-675	4.2	36
117	A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management. Expert Review of Endocrinology and Metabolism 2018 13 77-85	4.1	34

116	Operative management of locally advanced, differentiated thyroid cancer. Surgery, 2016, 160, 738-46	3.6	34
115	Time Course and Predictors of Structural Disease Progression in Pulmonary Metastases Arising from Follicular Cell-Derived Thyroid Cancer. <i>Thyroid</i> , 2016 , 26, 518-24	6.2	34
114	Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas. <i>Thyroid</i> , 2016 , 26, 1588-1597	6.2	34
113	Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. <i>Thyroid</i> , 2009 , 19, 1035-41	6.2	33
112	Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017 , 31, 295-305	6.5	32
111	Controversial Issues in Thyroid Cancer Management. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1187-1194	8.9	32
110	Oncologic outcomes after completion thyroidectomy for patients with well-differentiated thyroid carcinoma. <i>Annals of Surgical Oncology</i> , 2014 , 21, 1374-8	3.1	31
109	Cost-effectiveness analysis of papillary thyroid cancer surveillance. <i>Cancer</i> , 2015 , 121, 4132-40	6.4	31
108	Stage migration with the new American Joint Committee on Cancer (AJCC) staging system (8th edition) for differentiated thyroid cancer. <i>Surgery</i> , 2019 , 165, 6-11	3.6	30
107	Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer. <i>Thyroid</i> , 2018 , 28, 1293-1300	6.2	29
106	Changing trends in well differentiated thyroid carcinoma over eight decades. <i>International Journal of Surgery</i> , 2012 , 10, 618-23	7.5	29
105	Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: a practical approach to clinical decision making. <i>Oral Oncology</i> , 2013 , 49, 676-83	4.4	29
104	A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer. <i>Cancer Control</i> , 2011 , 18, 89-95	2.2	29
103	Treatment decision making in early-stage papillary thyroid cancer. <i>Psycho-Oncology</i> , 2018 , 27, 61-68	3.9	28
102	Using diffusion-weighted MRI to predict aggressive histological features in papillary thyroid carcinoma: a novel tool for pre-operative risk stratification in thyroid cancer. <i>Thyroid</i> , 2015 , 25, 672-80	6.2	27
101	Lateral Neck Lymph Node Characteristics Prognostic of Outcome in Patients with Clinically Evident N1b Papillary Thyroid Cancer. <i>Annals of Surgical Oncology</i> , 2015 , 22, 3530-6	3.1	27
100	Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence. <i>Thyroid</i> , 2015 , 25, 1235-42	6.2	25
99	Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging. <i>Oral Oncology</i> , 2013 , 49, 695-701	4.4	25

98	Thyroid Differentiated and Anaplastic Carcinoma 2017, 881-898		25
97	Frequent screening with serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant disease in the surveillance of intermediate risk papillary thyroid cancer patients without suspicious findings on follow-up ultrasound evaluation. <i>Journal of</i>	5.6	23
96	Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma. <i>Thyroid</i> , 2015 , 25, 503-8	6.2	22
95	Thyroid Cancer Treatment Choice: A Pilot Study of a Tool to Facilitate Conversations with Patients with Papillary Microcarcinomas Considering Treatment Options. <i>Thyroid</i> , 2018 , 28, 1325-1331	6.2	22
94	SERIAL NECK ULTRASOUND IS MORE LIKELY TO IDENTIFY FALSE-POSITIVE ABNORMALITIES THAN CLINICALLY SIGNIFICANT DISEASE IN LOW-RISK PAPILLARY THYROID CANCER PATIENTS. <i>Endocrine Practice</i> , 2015 , 21, 1372-9	3.2	22
93	ret/PTC activation is not associated with individual radiation dose estimates in a pilot study of neoplastic thyroid nodules arising in Russian children and adults exposed to Chernobyl fallout. <i>Thyroid</i> , 2008 , 18, 839-46	6.2	22
92	No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. <i>Diabetes Care</i> , 2018 , 41, 620-622	14.6	21
91	Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features. <i>Endocrine</i> , 2019 , 64, 97-108	4	20
90	Comparable outcomes for patients with pT1a and pT1b differentiated thyroid cancer: Is there a need for change in the AJCC classification system?. <i>Surgery</i> , 2014 , 156, 1484-9; discussion 1489-90	3.6	20
89	RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system. <i>Laryngoscope</i> , 2015 , 125, 2417-24	3.6	19
88	Response to Therapy Status Is an Excellent Predictor of Pregnancy-Associated Structural Disease Progression in Patients Previously Treated for Differentiated Thyroid Cancer. <i>Thyroid</i> , 2017 , 27, 396-407	1 ^{6.2}	17
87	How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. <i>Thyroid</i> , 2019 , 29, 1792-1	6.2 803	15
86	Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node Metastases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 4889-4899	5.6	15
85	Radioactive iodine therapy in poorly differentiated thyroid cancer. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 665-8		15
84	A Risk-adapted Approach to Follow-up in Differentiated Thyroid Cancer. <i>Rambam Maimonides Medical Journal</i> , 2016 , 7,	1.8	15
83	Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma?. <i>Surgery</i> , 2020 , 167, 10-17	3.6	15
82	Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. <i>Thyroid</i> , 2018 , 28, 1180-118	6.2	14
81	Treatment of thyroid cancer: 2007a basic review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 69, S92-7	4	14

(2021-2007)

80	Investigational therapies for metastatic thyroid carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, 641-6	7.3	14
79	Effectiveness of routine ultrasonographic surveillance of patients with low-risk papillary carcinoma of the thyroid. <i>Surgery</i> , 2016 , 159, 1390-5	3.6	13
78	Preoperative neck ultrasound in clinical node-negative differentiated thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3686-93	5.6	13
77	Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. <i>Modern Pathology</i> , 2020 , 33, 1690-1701	9.8	12
76	Challenges of Active Surveillance Protocols for Low-Risk Papillary Thyroid Microcarcinoma in the United States. <i>Thyroid</i> , 2016 , 26, 989-90	6.2	12
75	Screening for thyroid cancer in survivors of childhood and young adult cancer treated with neck radiation. <i>Journal of Cancer Survivorship</i> , 2017 , 11, 302-308	5.1	11
74	Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer. <i>Clinical Endocrinology</i> , 2017 , 87, 566-571	3.4	10
73	Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies. <i>Thyroid</i> , 2020 , 30, 1112-1119	6.2	10
72	Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting. <i>Human Pathology</i> , 2021 , 110, 62-72	3.7	10
71	Active surveillance for patients with very low-risk thyroid cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2020 , 5, 175-182	2.8	9
70	Dynamic contrast-enhanced MRI model selection for predicting tumor aggressiveness in papillary thyroid cancers. <i>NMR in Biomedicine</i> , 2020 , 33, e4166	4.4	9
69	Ethical Considerations When Counseling Patients With Thyroid Cancer About Surgery vs Observation. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016 , 142, 406-7	3.9	9
68	Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of	4.2	9
67	Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Clinical Assessment and Risk Stratification in Differentiated Thyroid Cancer. Endocrinology and Liety Metabolism Clinics of North America, 2019, 48, 99-10821.	5.5	8
66	Recombinant human thyroid-stimulating hormone to stimulate 131-I uptake for remnant ablation and adjuvant therapy. <i>Endocrine Practice</i> , 2013 , 19, 149-56	3.2	8
65	Management of Retropharyngeal Lymph Node Metastases in Differentiated Thyroid Carcinoma. <i>Thyroid</i> , 2020 , 30, 688-695	6.2	8
64	Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer. <i>Molecular Imaging and Radionuclide Therapy</i> , 2017 , 26, 80-86	0.8	7
63	A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer.	6.2	7

62	American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. <i>Head and Neck</i> , 2019 , 41, 843-856	4.2	7
61	Similarities and differences in follicular cell-derived thyroid cancer management guidelines used in Europe and the United States. <i>Seminars in Nuclear Medicine</i> , 2011 , 41, 89-95	5.4	6
60	Differentiated Thyroid Carcinoma That Express Sodium-Iodide Symporter Have a Lower Risk of Recurrence for Children and Adolescents		6
59	The Prognostic Significance of Nodal Metastases from Papillary Thyroid Carcinoma can be Stratified Based on the Size and Number of Metastatic Lymph Nodes, as Well as the Presence of Extranodal Extension ATA Surgical Affairs Committee Taskforce on Thyroid Cancer Nodal Surgery.	6.2	6
58	Prophylactic Lateral Neck Dissection for Medullary Thyroid Carcinoma is not Associated with Improved Survival. <i>Annals of Surgical Oncology</i> , 2021 , 28, 6572-6579	3.1	6
57	Assessing the Number of Candidates There Are for Active Surveillance of Low-risk Papillary Thyroid Cancers in the US. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020 , 146, 585-586	3.9	5
56	Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to Healthcare. <i>Thyroid</i> , 2015 , 25, 865-6	6.2	5
55	Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer. <i>Indian Journal of Surgical Oncology</i> , 2012 , 3, 182-9	0.7	5
54	Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial <i>Thyroid</i> , 2022 ,	6.2	5
53	Restricting ultrasound thyroid fine needle aspiration biopsy by nodule size: which tumors are we missing? A population-based study. <i>Endocrine</i> , 2016 , 51, 499-505	4	4
52	Patients with Multifocal Macroscopic Papillary Thyroid Carcinoma Have a Low Risk of Recurrence at Early Follow-Up after Total Thyroidectomy and Radioactive Iodine Treatment. <i>European Thyroid Journal</i> , 2017 , 6, 31-39	4.2	4
51	Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary.	2.9	4
50	Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma. <i>Annals of Surgical Oncology</i> , 2019 , 26, 4423-4429	3.1	4
49	ATA HIGH-RISK THYROID CANCER PATIENTS DEMONSTRATING AN EXCELLENT RESPONSE TO THERAPY WITHIN A FEW WEEKS OF INITIAL THERAPY HAVE BETTER THAN EXPECTED CLINICAL OUTCOMES. <i>Endocrine Practice</i> , 2019 , 25, 287-289	3.2	4
48	Previous External Beam Radiation Treatment Exposure Does Not Confer Worse Outcome for Patients with Differentiated Thyroid Cancer. <i>Thyroid</i> , 2017 , 27, 412-417	6.2	4
47	Invasion of a Recurrent Laryngeal Nerve from Small Well-Differentiated Papillary Thyroid Cancers: Patient Selection Implications for Active Surveillance. <i>Thyroid</i> , 2021 ,	6.2	4
46	Distinguishing remnant ablation from adjuvant treatment in differentiated thyroid cancer. <i>Lancet Diabetes and Endocrinology,the</i> , 2019 , 7, 7-8	18.1	4
45	Is a Prophylactic Central Compartment Neck Dissection Required in Papillary Thyroid Carcinoma Patients with Clinically Involved Lateral Compartment Lymph Nodes?. <i>Annals of Surgical Oncology</i> , 2021 , 28, 512-518	3.1	4

(2010-2018)

44	Implementing Key Changes in the American Thyroid Association 2015 Thyroid Nodules/Differentiated Thyroid Cancer Guidelines Across Practice Types. <i>Endocrine Practice</i> , 2018 , 24, 833-840	3.2	4
43	Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA) <i>Journal of Clinical Oncology</i> , 2022 , JCO2100714	2.2	4
42	Surgical Management of Low-/Intermediate-Risk Node Negative Thyroid Cancer: A Single-Institution Study Using Propensity Matching Analysis to Compare Thyroid Lobectomy and Total Thyroidectomy. <i>Thyroid</i> , 2021 ,	6.2	3
41	Papillary thyroid microcarcinoma and active surveillance - Authors' reply. <i>Lancet Diabetes and Endocrinology,the</i> , 2016 , 4, 976-977	18.1	2
40	Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive Iodine. <i>European Endocrinology</i> , 2017 , 13, 26-29	3.4	2
39	How Does The AJCC/TNM Staging System Eighth Edition Perform in Thyroid Cancer at A Major Middle Eastern Medical Center?. <i>Endocrine Practice</i> , 2021 , 27, 607-613	3.2	2
38	Does macroscopic extrathyroidal extension to the strap muscles alone affect survival in papillary thyroid carcinoma?. <i>Surgery</i> , 2021 ,	3.6	2
37	Can risk-adapted treatment recommendations replace the 'one size fits all' approach for early-stage thyroid cancer patients?. <i>Oncology</i> , 2009 , 23, 592, 600, 603	1.8	2
36	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment <i>Head and Neck</i> , 2022 ,	4.2	2
35	An Overview of the Management of Thyroid Cancer 2010 , 104-116		1
34	Pathological Spectrum of Parathyroid Disease 2010 , 175-180		1
33	Pathological Spectrum of Thyroid Disease 2010 , 14-24		1
32	ThyroidEx: Development and Preliminary Validation of a Thyroid Surgery Expectations Measure. <i>Otolaryngology - Head and Neck Surgery</i> , 2021 , 165, 267-274	5.5	1
31	Ultrasound-Guided Percutaneous Laser Ablation of the Thyroid Gland in a Swine Model: Comparison of Ablation Parameters and Ablation Zone Dimensions. <i>CardioVascular and Interventional Radiology</i> , 2021 , 44, 1798-1806	2.7	1
30	Perioperative diagnostics of patients referred for radioiodine therapy of differentiated thyroid carcinoma: referral center experience in an iodine-insufficient country. <i>Endocrine</i> , 2021 , 72, 721-726	4	1
29	Frequent neck US in papillary thyroid cancer likely detects non-actionable findings. <i>Clinical Endocrinology</i> , 2021 , 94, 504-512	3.4	1
28	Risk Stratification in Differentiated Thyroid Cancer: Importance and Clinical Implications of Preoperative Risk Stratification. <i>VideoEndocrinology</i> , 2018 , 5,	1.6	1
27	Symptoms, Differential Diagnosis and Management 2010 , 143-163		O

26	Patient Perspectives on the Extent of Surgery and Radioactive Iodine Treatment for Low-Risk Differentiated Thyroid Cancer. <i>Endocrine Practice</i> , 2021 , 27, 383-389	3.2	О
25	Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. <i>Cancer</i> , 2021 , 127, 4161-4170	6.4	O
24	The "broken chair" in patients with differentiated thyroid cancer. <i>Endocrine</i> , 2017 , 57, 359-360	4	
23	Response to Letter: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2115-2116	5.6	
22	Response to: Letter to the Editor Regarding the Article "Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma". <i>Thyroid</i> , 2015 , 25, 1269-70	6.2	
21	Reply: Active Surveillance in Micropapillary Carcinoma. <i>Surgery</i> , 2018 , 163, 1325-1329	3.6	
20	Clinical Anatomy, Developmental Aberrations and Endocrinology 2010 , 181-188		
19	Management of Parathyroid Disease 2010 , 189-197		
18	Thyroid Imaging 2010 , 36-44		
17	Surgical Management of Benign Thyroid Disease 2010 , 77-86		
16	The Role of Nuclear Medicine 2010 , 45-54		
15	Thyroid Cytopathology 2010 , 25-35		
14	Symptoms, Assessment and Guidelines for Primary Care Referral 2010 , 1-13		
13	Endocrine Disorders: Medical Management 2010 , 55-64		
12	Oncogenesis and Molecular Targeted Therapy in Thyroid Cancer 2010 , 87-103		
11	Clinical Anatomy and Developmental Aberrations 2010 , 65-76		
10	Surgical Management of Thyroid Cancer 2010 , 117-124		
9	Medical Management of Thyroid Cancer 2010 , 125-141		

LIST OF PUBLICATIONS

8 Postoperative Management of Well-Differentiated Thyroid Cancer **2009**, 137-148

7	Enhanced interdisciplinary communication: development of an interactive thyroid nodule/cancer disease map. <i>Laryngoscope</i> , 2019 , 129, 269-274	3.6
6	Commentary: Re-recurrence after surgical management of recurrent thyroid cancer. <i>Surgery</i> , 2021 , 169, 844-845	3.6
5	Hemithyroidectomy for Differentiated Thyroid Cancer 2021 , 67-80	
4	Papillary Carcinoma Observation 2021 , 199-203.e1	
3	Risk Stratification and Current Management of Low Risk Thyroid Cancer 2018 , 111-120	
2	Nuances in the Surgical Management of Thyroid Cancer <i>Indian Journal of Surgical Oncology</i> , 2022 , 13, 1-6	0.7
1	Dynamic Risk Group Analysis and Staging for Differentiated Thyroid Cancer 2021 , 218-224.e1	